BiotechTV - News SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
Jan 12, 2026
Vlad Coric, Chairman and CEO of Biohaven and an expert in neurology and immunology, dives into the company’s innovative pipeline. He highlights the degrader programs targeting immunology and discusses a brain-penetrant TYK2/JAK1 inhibitor for Parkinson's. Coric also shares insights about a myostatin approach to tackle obesity and preserve muscle, and the promising Kv7 epilepsy program, emphasizing upcoming trial data. His commitment to ataxia patients and navigating FDA challenges adds depth to this engaging conversation.
AI Snips
Chapters
Transcript
Episode notes
Eight-Year Commitment To Ataxia Patients
- Vlad Coric described eight years of commitment to developing a treatment for a rare neurodegenerative ataxia.
- He published the full FDA interaction timeline to be transparent and advocate for patients.
Inconsistent FDA Standards For Rare Diseases
- Coric highlighted inconsistent application of regulatory flexibility across FDA divisions for rare diseases.
- He argued some divisions use common-disease standards, which can block approvals despite compelling rare-disease data.
Focus Investors On The Pipeline, Not One Setback
- Coric urged investors to focus on Biohaven's future pipeline while the company continues regulatory engagement.
- He recommended staying tuned for 2026 updates as they pursue approval or shift focus to other programs.